Cargando…
Epirubicin–vinorelbine vs FEC100 for node-positive, early breast cancer: French Adjuvant Study Group 09 trial
The aim of the study was to compare our reference adjuvant chemotherapy, FEC100 (fluorouracil 500 mg m(−2), epirubicin 100 mg m(−2) and cyclophosphamide 500 mg m(−2), six cycles every 21 days), to an epirubicin–vinorelbine (Epi-Vnr) combination for early, poor-prognosis breast cancer patients. Patie...
Autores principales: | Kerbrat, P, Roché, H, Bonneterre, J, Veyret, C, Lortholary, A, Monnier, A, Fumoleau, P, Fargeot, P, Namer, M, Chollet, P, Goudier, M-J, Audhuy, B, Simon, H, Montcuquet, P, Eymard, J-C, Walter, S, Clavère, P, Guastalla, J-P |
---|---|
Formato: | Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group
2007
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2359910/ https://www.ncbi.nlm.nih.gov/pubmed/17505516 http://dx.doi.org/10.1038/sj.bjc.6603773 |
Ejemplares similares
-
Docetaxel vs 5-fluorouracil plus vinorelbine in metastatic breast cancer after anthracycline therapy failure
por: Bonneterre, J, et al.
Publicado: (2002) -
Sequential or alternating administration of docetaxel (Taxotere®) combined with FEC in metastatic breast cancer: a randomised phase II trial
por: Spielmann, M, et al.
Publicado: (2002) -
Phase II multicentre randomised study of docetaxel plus epirubicin vs 5-fluorouracil plus epirubicin and cyclophosphamide in metastatic breast cancer
por: Bonneterre, J, et al.
Publicado: (2004) -
Phase I study of lapatinib plus vinorelbine in patients with locally advanced or metastatic breast cancer overexpressing HER2
por: Brain, E, et al.
Publicado: (2012) -
FEC91#27 Migration FEC vers DSC
por: Frammery, B, et al.
Publicado: (1991)